Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.72 |
| ▸ | RAB9A | P51151 | 10/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.68 |
| ▸ | RELA | Q04206 | 5/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21982901 | 0.88 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL7301810 | 0.84 | KMT2A (0.67) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL7306324 | 0.84 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL12523461 | 0.84 | KMT2A (0.67) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL32681139 | 0.84 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL1787983 | 0.81 | HRH3 (0.55) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL11961607 | 0.81 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL7300048 | 0.81 | RAB9A (0.74) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL14863153 | 0.81 | PLAU (0.61) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL15508206 | 0.81 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | NPC1 2020/4885RAB9A 4036/4885SMN1; SMN2 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.